Ariad Ruling Bolsters Written Description Requirement
By Abigail Rubenstein ( March 23, 2010, 7:14 PM EDT) -- While the ruling in Ariad Pharmaceuticals Inc.'s closely watched patent infringement case against Eli Lilly & Co. confirmed existing law, intellectual property attorneys say the court's decision will shine a spotlight on the U.S. Patent Act's written description requirement — both for patent seekers and for defendants facing accusations of infringement....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.